Loading…

Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients

The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 2011, Vol.30 (1), p.103-108
Main Authors: Conde-Estévez, D, Grau, S, Albanell, J, Terradas, R, Salvadó, M, Knobel, H
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953
cites cdi_FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953
container_end_page 108
container_issue 1
container_start_page 103
container_title European journal of clinical microbiology & infectious diseases
container_volume 30
creator Conde-Estévez, D
Grau, S
Albanell, J
Terradas, R
Salvadó, M
Knobel, H
description The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university-affiliated hospital. We performed univariate comparisons between the two groups and then multivariate analysis to identify patient risk factors for E. faecium isolation. Seventy-three patients were included in the analysis: 54 (74.0%) with bacteraemia caused by E. faecalis and 19 (26.0%) by E. faecium. The Simplified Acute Physiological Score (SAPS) value was significantly greater in E. faecium isolates (40.7 vs. 35.2; p = 0.009). Diabetes mellitus was more frequently diagnosed in patients with E. faecium bacteraemia (52.6% vs. 24.1%; p = 0.021). Prior penicillin exposure was more frequent in patients with E. faecium bacteraemia (68.4% vs. 29.6%; p = 0.003). There was a trend toward higher mortality in E. faecium bacteraemia patients (47.4% vs. 25.9%; p = 0.084). Independent patient risk factors for E. faecium isolation were prior penicillin exposure (odds ratio [OR], 6.479; p = 0.003) and SAPS > 34 (OR, 6.896; p = 0.009). When compared to E. faecalis bacteraemia, E. faecium bacteraemia in cancer patients is independently associated with more severe illness and prior use of penicillins; therefore, empiric treatment which would cover E. faecium should be considered in cancer patients suspected of having bacteraemia.
doi_str_mv 10.1007/s10096-010-1029-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_888093943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>888093943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953</originalsourceid><addsrcrecordid>eNqFkl1rFTEQhoMotlZ_gDcaBPFqNZOPzeZSDvUDCl5or0NONtum7CbHZLfS3-KfdU732IKC3iSEeeadmXdCyHNgb4Ex_a7iadqGAWuAcdOoB-QYpFCNFFo8JMfMCNkYzcUReVLrFcOcTuvH5IgzDaCNOiY_N2NM0buR-ktXnJ9DiXWOvlKXepqX2ecpVJoHunNzDGmu9EecL-m1Sxi58TE1dak-7Oa4HQM9TSiQffZ-qXRwAYXjKvVXJC4T3d4WdGGKjsZEPYqGclfpKXk0uLGGZ4f7hJx_OP22-dScffn4efP-rPFStXPTSW50DxyUVxoNYQDcd32QwHzoghC9CZ2TimnXq95Jvx3QLe5b0fbBGyVOyJtVd1fy9yXU2U4RRxpHl0Jequ26Dp00UvyfhFYbiS4j-eoP8iovJeEYe0gYoYAhBCvkS661hMHuSpxcubHA7H7Ddt2wZbdvbuy-2RcH4WU7hf4u4_dKEXh9AFxF-4eCpsZ6z4lOSNECcnzlKobSRSj3Hf6r-ss1aXDZugv8K_b8K2cgGBi8DIhfWCTJhA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>816393510</pqid></control><display><type>article</type><title>Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients</title><source>Springer Nature</source><creator>Conde-Estévez, D ; Grau, S ; Albanell, J ; Terradas, R ; Salvadó, M ; Knobel, H</creator><creatorcontrib>Conde-Estévez, D ; Grau, S ; Albanell, J ; Terradas, R ; Salvadó, M ; Knobel, H</creatorcontrib><description>The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university-affiliated hospital. We performed univariate comparisons between the two groups and then multivariate analysis to identify patient risk factors for E. faecium isolation. Seventy-three patients were included in the analysis: 54 (74.0%) with bacteraemia caused by E. faecalis and 19 (26.0%) by E. faecium. The Simplified Acute Physiological Score (SAPS) value was significantly greater in E. faecium isolates (40.7 vs. 35.2; p = 0.009). Diabetes mellitus was more frequently diagnosed in patients with E. faecium bacteraemia (52.6% vs. 24.1%; p = 0.021). Prior penicillin exposure was more frequent in patients with E. faecium bacteraemia (68.4% vs. 29.6%; p = 0.003). There was a trend toward higher mortality in E. faecium bacteraemia patients (47.4% vs. 25.9%; p = 0.084). Independent patient risk factors for E. faecium isolation were prior penicillin exposure (odds ratio [OR], 6.479; p = 0.003) and SAPS &gt; 34 (OR, 6.896; p = 0.009). When compared to E. faecalis bacteraemia, E. faecium bacteraemia in cancer patients is independently associated with more severe illness and prior use of penicillins; therefore, empiric treatment which would cover E. faecium should be considered in cancer patients suspected of having bacteraemia.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-010-1029-5</identifier><identifier>PMID: 20711795</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacteremia - drug therapy ; Bacteremia - epidemiology ; Bacteremia - microbiology ; Bacteremia - pathology ; Bacterial diseases ; Bacterial sepsis ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Brief Report ; Cancer therapies ; Enterococcus faecalis ; Enterococcus faecalis - drug effects ; Enterococcus faecalis - isolation &amp; purification ; Enterococcus faecium ; Enterococcus faecium - drug effects ; Enterococcus faecium - isolation &amp; purification ; Epidemiology ; Female ; Gram-Positive Bacterial Infections - drug therapy ; Gram-Positive Bacterial Infections - epidemiology ; Gram-Positive Bacterial Infections - microbiology ; Gram-Positive Bacterial Infections - pathology ; Hospitals ; Hospitals, University ; Human bacterial diseases ; Humans ; Infectious diseases ; Intensive care ; Internal Medicine ; Male ; Medical Microbiology ; Medical sciences ; Middle Aged ; Mortality ; Multivariate analysis ; Neoplasms - complications ; Nosocomial infections ; Pathogens ; Patients ; Penicillin ; Pharmacology. Drug treatments ; Pharmacy ; Physiology ; Regression analysis ; Retrospective Studies ; Risk Factors ; Severity of Illness Index ; Spain - epidemiology ; Treatment Outcome</subject><ispartof>European journal of clinical microbiology &amp; infectious diseases, 2011, Vol.30 (1), p.103-108</ispartof><rights>Springer-Verlag 2010</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953</citedby><cites>FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23834361$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20711795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conde-Estévez, D</creatorcontrib><creatorcontrib>Grau, S</creatorcontrib><creatorcontrib>Albanell, J</creatorcontrib><creatorcontrib>Terradas, R</creatorcontrib><creatorcontrib>Salvadó, M</creatorcontrib><creatorcontrib>Knobel, H</creatorcontrib><title>Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients</title><title>European journal of clinical microbiology &amp; infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university-affiliated hospital. We performed univariate comparisons between the two groups and then multivariate analysis to identify patient risk factors for E. faecium isolation. Seventy-three patients were included in the analysis: 54 (74.0%) with bacteraemia caused by E. faecalis and 19 (26.0%) by E. faecium. The Simplified Acute Physiological Score (SAPS) value was significantly greater in E. faecium isolates (40.7 vs. 35.2; p = 0.009). Diabetes mellitus was more frequently diagnosed in patients with E. faecium bacteraemia (52.6% vs. 24.1%; p = 0.021). Prior penicillin exposure was more frequent in patients with E. faecium bacteraemia (68.4% vs. 29.6%; p = 0.003). There was a trend toward higher mortality in E. faecium bacteraemia patients (47.4% vs. 25.9%; p = 0.084). Independent patient risk factors for E. faecium isolation were prior penicillin exposure (odds ratio [OR], 6.479; p = 0.003) and SAPS &gt; 34 (OR, 6.896; p = 0.009). When compared to E. faecalis bacteraemia, E. faecium bacteraemia in cancer patients is independently associated with more severe illness and prior use of penicillins; therefore, empiric treatment which would cover E. faecium should be considered in cancer patients suspected of having bacteraemia.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - epidemiology</subject><subject>Bacteremia - microbiology</subject><subject>Bacteremia - pathology</subject><subject>Bacterial diseases</subject><subject>Bacterial sepsis</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brief Report</subject><subject>Cancer therapies</subject><subject>Enterococcus faecalis</subject><subject>Enterococcus faecalis - drug effects</subject><subject>Enterococcus faecalis - isolation &amp; purification</subject><subject>Enterococcus faecium</subject><subject>Enterococcus faecium - drug effects</subject><subject>Enterococcus faecium - isolation &amp; purification</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gram-Positive Bacterial Infections - drug therapy</subject><subject>Gram-Positive Bacterial Infections - epidemiology</subject><subject>Gram-Positive Bacterial Infections - microbiology</subject><subject>Gram-Positive Bacterial Infections - pathology</subject><subject>Hospitals</subject><subject>Hospitals, University</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Intensive care</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Neoplasms - complications</subject><subject>Nosocomial infections</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Penicillin</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacy</subject><subject>Physiology</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Spain - epidemiology</subject><subject>Treatment Outcome</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFkl1rFTEQhoMotlZ_gDcaBPFqNZOPzeZSDvUDCl5or0NONtum7CbHZLfS3-KfdU732IKC3iSEeeadmXdCyHNgb4Ex_a7iadqGAWuAcdOoB-QYpFCNFFo8JMfMCNkYzcUReVLrFcOcTuvH5IgzDaCNOiY_N2NM0buR-ktXnJ9DiXWOvlKXepqX2ecpVJoHunNzDGmu9EecL-m1Sxi58TE1dak-7Oa4HQM9TSiQffZ-qXRwAYXjKvVXJC4T3d4WdGGKjsZEPYqGclfpKXk0uLGGZ4f7hJx_OP22-dScffn4efP-rPFStXPTSW50DxyUVxoNYQDcd32QwHzoghC9CZ2TimnXq95Jvx3QLe5b0fbBGyVOyJtVd1fy9yXU2U4RRxpHl0Jequ26Dp00UvyfhFYbiS4j-eoP8iovJeEYe0gYoYAhBCvkS661hMHuSpxcubHA7H7Ddt2wZbdvbuy-2RcH4WU7hf4u4_dKEXh9AFxF-4eCpsZ6z4lOSNECcnzlKobSRSj3Hf6r-ss1aXDZugv8K_b8K2cgGBi8DIhfWCTJhA</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Conde-Estévez, D</creator><creator>Grau, S</creator><creator>Albanell, J</creator><creator>Terradas, R</creator><creator>Salvadó, M</creator><creator>Knobel, H</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>2011</creationdate><title>Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients</title><author>Conde-Estévez, D ; Grau, S ; Albanell, J ; Terradas, R ; Salvadó, M ; Knobel, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - epidemiology</topic><topic>Bacteremia - microbiology</topic><topic>Bacteremia - pathology</topic><topic>Bacterial diseases</topic><topic>Bacterial sepsis</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brief Report</topic><topic>Cancer therapies</topic><topic>Enterococcus faecalis</topic><topic>Enterococcus faecalis - drug effects</topic><topic>Enterococcus faecalis - isolation &amp; purification</topic><topic>Enterococcus faecium</topic><topic>Enterococcus faecium - drug effects</topic><topic>Enterococcus faecium - isolation &amp; purification</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gram-Positive Bacterial Infections - drug therapy</topic><topic>Gram-Positive Bacterial Infections - epidemiology</topic><topic>Gram-Positive Bacterial Infections - microbiology</topic><topic>Gram-Positive Bacterial Infections - pathology</topic><topic>Hospitals</topic><topic>Hospitals, University</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Intensive care</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Neoplasms - complications</topic><topic>Nosocomial infections</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Penicillin</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacy</topic><topic>Physiology</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Spain - epidemiology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conde-Estévez, D</creatorcontrib><creatorcontrib>Grau, S</creatorcontrib><creatorcontrib>Albanell, J</creatorcontrib><creatorcontrib>Terradas, R</creatorcontrib><creatorcontrib>Salvadó, M</creatorcontrib><creatorcontrib>Knobel, H</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical microbiology &amp; infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conde-Estévez, D</au><au>Grau, S</au><au>Albanell, J</au><au>Terradas, R</au><au>Salvadó, M</au><au>Knobel, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients</atitle><jtitle>European journal of clinical microbiology &amp; infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2011</date><risdate>2011</risdate><volume>30</volume><issue>1</issue><spage>103</spage><epage>108</epage><pages>103-108</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university-affiliated hospital. We performed univariate comparisons between the two groups and then multivariate analysis to identify patient risk factors for E. faecium isolation. Seventy-three patients were included in the analysis: 54 (74.0%) with bacteraemia caused by E. faecalis and 19 (26.0%) by E. faecium. The Simplified Acute Physiological Score (SAPS) value was significantly greater in E. faecium isolates (40.7 vs. 35.2; p = 0.009). Diabetes mellitus was more frequently diagnosed in patients with E. faecium bacteraemia (52.6% vs. 24.1%; p = 0.021). Prior penicillin exposure was more frequent in patients with E. faecium bacteraemia (68.4% vs. 29.6%; p = 0.003). There was a trend toward higher mortality in E. faecium bacteraemia patients (47.4% vs. 25.9%; p = 0.084). Independent patient risk factors for E. faecium isolation were prior penicillin exposure (odds ratio [OR], 6.479; p = 0.003) and SAPS &gt; 34 (OR, 6.896; p = 0.009). When compared to E. faecalis bacteraemia, E. faecium bacteraemia in cancer patients is independently associated with more severe illness and prior use of penicillins; therefore, empiric treatment which would cover E. faecium should be considered in cancer patients suspected of having bacteraemia.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>20711795</pmid><doi>10.1007/s10096-010-1029-5</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0934-9723
ispartof European journal of clinical microbiology & infectious diseases, 2011, Vol.30 (1), p.103-108
issn 0934-9723
1435-4373
language eng
recordid cdi_proquest_miscellaneous_888093943
source Springer Nature
subjects Aged
Aged, 80 and over
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacology
Antibacterial agents
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacteremia - drug therapy
Bacteremia - epidemiology
Bacteremia - microbiology
Bacteremia - pathology
Bacterial diseases
Bacterial sepsis
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Brief Report
Cancer therapies
Enterococcus faecalis
Enterococcus faecalis - drug effects
Enterococcus faecalis - isolation & purification
Enterococcus faecium
Enterococcus faecium - drug effects
Enterococcus faecium - isolation & purification
Epidemiology
Female
Gram-Positive Bacterial Infections - drug therapy
Gram-Positive Bacterial Infections - epidemiology
Gram-Positive Bacterial Infections - microbiology
Gram-Positive Bacterial Infections - pathology
Hospitals
Hospitals, University
Human bacterial diseases
Humans
Infectious diseases
Intensive care
Internal Medicine
Male
Medical Microbiology
Medical sciences
Middle Aged
Mortality
Multivariate analysis
Neoplasms - complications
Nosocomial infections
Pathogens
Patients
Penicillin
Pharmacology. Drug treatments
Pharmacy
Physiology
Regression analysis
Retrospective Studies
Risk Factors
Severity of Illness Index
Spain - epidemiology
Treatment Outcome
title Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T00%3A05%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20characteristics%20and%20outcomes%20of%20patients%20with%20vancomycin-susceptible%20Enterococcus%20faecalis%20and%20Enterococcus%20faecium%20bacteraemia%20in%20cancer%20patients&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Conde-Est%C3%A9vez,%20D&rft.date=2011&rft.volume=30&rft.issue=1&rft.spage=103&rft.epage=108&rft.pages=103-108&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-010-1029-5&rft_dat=%3Cproquest_cross%3E888093943%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=816393510&rft_id=info:pmid/20711795&rfr_iscdi=true